Support The Moscow Times!

Russian Market Boosts Drug Maker Stada's Q3

German generic drug maker Stada posted a 7 percent rise in nine-month adjusted core earnings, as higher sales of drugs in Russia offset a decline in its domestic market.

Adjusted earnings before interest, tax, depreciation and amortization, or EBITDA, rose to 284 million euros ($397 million) in the first nine months of 2013, just shy of market expectations for 287 million euros.

Stada still sees high single-digit percentage growth in full-year adjusted EBITDA and it confirmed its target for 2014 net income of 215 million euros, up from 86.5 million in 2012.

Read more

We need your help now more than ever.

Independent media outlets and journalists in Russia are being increasingly targeted with “foreign agent” and “undesirable” labels, threatening the existence of the free press day by day.

Your donation to The Moscow Times directly supports the last independent English-language news source within Russia.